The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.

Détails

Ressource 1Télécharger: 35292514_BIB_5157B6387D0C.pdf (3136.57 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_5157B6387D0C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Périodique
Journal for immunotherapy of cancer
Auteur⸱e⸱s
Sum E., Rapp M., Dürr H., Mazumdar A., Romero P.J., Trumpfheller C., Umaña P.
ISSN
2051-1426 (Electronic)
ISSN-L
2051-1426
Statut éditorial
Publié
Date de publication
03/2022
Peer-reviewed
Oui
Volume
10
Numéro
3
Pages
e003264
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Tumor-targeted CD40 agonism represents an attractive strategy for cancer immunotherapy (CIT) as it promotes dendritic cell (DC) activation and concomitant tumor-specific T cell priming without causing systemic side effects. We developed the bispecific CD40 agonistic antibody CEA-CD40, which triggers CD40 stimulation exclusively in the presence of carcinoembryonic antigen (CEA), a glycoprotein specifically expressed on tumor cells. In this study, we demonstrate that CEA-CD40 can enable potent in vitro DC activation and consecutive T cell cross-priming in a CEA-specific manner. Furthermore, we provide evidence that CEA-CD40 increases colocalization of CEA <sup>+</sup> tumor material and DCs. Using CEA <sup>+</sup> tumor-derived extracellular vesicles (EVs), which are known to be an excellent tumor antigen source, we show that CEA-CD40 mediates delivery of CEA <sup>+</sup> EVs to DCs. Importantly, our data indicates that this fosters acquisition of tumor EV major histocompatibility complex I/peptide complexes by DCs, consequently improving CD8 <sup>+</sup> T cell priming against EV-associated antigen in vitro. Thus, we provide mechanistic evidence for a dual mode of action of CEA-CD40 for CIT: we suggest that CEA-CD40 has the potential to activate DCs and in addition can promote their loading with tumor antigen derived from EVs to trigger tumor-specific T cell cross-priming.
Mots-clé
CD40 Antigens, CD8-Positive T-Lymphocytes, Carcinoembryonic Antigen, Dendritic Cells, Humans, Neoplasms/therapy, adaptive immunity, dendritic cells, drug evaluation, preclinical, immunotherapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/03/2022 8:46
Dernière modification de la notice
25/01/2024 7:36
Données d'usage